Currently browsing tag

closing-price

Celgene to invest $1 billion in Juno to partner in cancer therapies

Celgene Corp on Monday launched a 10-year partnership with Juno Therapeutics, announcing a $1 billion investment aimed at bringing to market Juno technologies that harness the immune system to treat cancer and autoimmune diseases. The huge vote of confidence propelled Juno’s shares more than 40 percent higher to $65.75 in heavy extended trading. Celgene will pay Juno about $150 million upfront and buy about 9.1 million newly issued Juno shares at $93 each, double Juno’s closing price on Monday.

Philips to buy medical device maker Volcano for $1.2 billion

AMSTERDAM (Reuters) – Philips has agreed to acquire U.S.-based medical device maker Volcano Corp for $1.2 billion including debt, its largest healthcare acquisition in seven years and an effort to cash in on more complex treatments for an aging population. Philips said the acquisition would lead to synergies in research and development and sales, and would add to Philips' earnings per share by 2017. The offer, a public tender of $18 per share, is at a premium of about 57 percent to Volcano's closing price on Tuesday. …